trending Market Intelligence /marketintelligence/en/news-insights/trending/jv8j2twes3tastt80s4a4q2 content esgSubNav
In This List

Edge Therapeutics gets Nasdaq noncompliance notice

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Edge Therapeutics gets Nasdaq noncompliance notice

Edge Therapeutics Inc. received a notice of noncompliance from Nasdaq for failing to meet the stock exchange's minimum $1 bid price listing standard.

The exchange granted Edge Therapeutics 180 calendar days, or until March 4, 2019, to regain compliance with the rule.

The Berkeley Heights, N.J.-based biotechnology said the notice has no immediate effect on its common stock which trades under the EDGE symbol on the Nasdaq Global Select Market.